Physician profile
Ashanti E Smith
NPI 1073821567
$644.95
in general payments reported to CMS, 2019-2025
19 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.87 · 2021: $41.94 · 2022: $26.18 · 2023: $83.59 · 2024: $163 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $99.73 | 2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $92.13 | 2024-2025 | |
| Abbvie INC. | $60.62 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $50.95 | 2024-2025 | |
| Mylan Specialty L.P. | $38.30 | 2024 | Yupelri |
| Lilly USA, LLC | $37.29 | 2023 | Trulicity, Mounjaro |
| Amgen INC. | $36.17 | 2023-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $29.09 | 2021-2024 | |
| Ultragenyx Pharmaceutical INC. | $23.25 | 2024 | Crysvita |
| Organon LLC | $22.93 | 2024-2025 | Nexplanon |
| Dexcom, INC. | $22.83 | 2025 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $20.34 | 2025 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $19.09 | 2024 | Xarelto |
| Phadia US INC. | $18.77 | 2025 | Immunocap |
| Glaxosmithkline, LLC. | $18.00 | 2023 | Arexvy, Shingrix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16.73 | 2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $14.33 | 2023 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $12.42 | 2021 | |
| Phathom Pharmaceuticals, INC. | $11.98 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashanti Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.